Sorted By Test Name - Mayo Medical Laboratories

LBC
60450
utilizing the platelet channel and used to estimate fetal lung maturity.
Useful For: Predicting fetal lung maturity and assessing the risk of developing neonatal respiratory
distress syndrome, when performed during 32 to 39 weeks gestation Useful in cases in which lamellar
body count results are indeterminate
Interpretation: Lamellar body count (LBC): Amniotic fluid LBC >50,000/mcL is predictive of fetal
lung maturity. Amniotic fluid LBC or = 2.5
and PG absent: indeterminate LS ratio < 2.5 and PG trace: indeterminate L/S ratio > or = 2.5 and PG
trace: mature PG present: mature
Reference Values:
Immature: 50,000/mcL
Cutoffs are based on consensus protocol (Neerhof M, Dohnal JC, Ashwood ER, et al: Lamellar body
counts: a consensus on protocol. Obstet Gynecol 2001;97:318-320)
Clinical References: 1. Fetal Lung Maturity. ACOG Practice bulletin. Obstet Gynecol September
2008;112(3):717-726 2. Eby C, Lu J, Gronowski AM: Lamellar Body Counts Performed on Automated
Hematology Analyzers to Assess Fetal Lung Maturity. Lab Med 2008;39(7):15 3. Haymond S, Luzzi V,
Parvin C, Gronowski A: A Direct Comparison Between Lamellar Body Counts and Fluorescent
Polarization Methods for Predicting Respiratory Distress Syndrome. Am J Clin Pathol 2006;126:894-899
4. Szallasi A, Gronowski A, Eby C: Lamellar Body Count in Amniotic Fluid: A Comparative Study of
Four Different Hematology Analyzers. Clin Chem 2003;49(6):994-997 5. Grenache DG, Gronowski AM:
Fetal lung maturity. Clin Biochem 2006;39:1-10 6. Neerhof M, Dohnal JC, Ashwood ER, et al: Lamellar
body counts: a consensus on protocol. Obstet Gynecol 2001;97:318-320
Lamellar Body Count, Amniotic Fluid
Clinical Information: Fetal lung maturity testing is used to determine the risk for developing
respiratory distress syndrome (RDS) in infants born prematurely (32-39 weeks). The risk for developing
RDS is inversely related to gestational age and is the most common cause of respiratory failure in
neonates. RDS is associated with preterm birth due to insufficient production of pulmonary surfactant.
Pulmonary surfactant is synthesized by type II pneumocytes. Surfactant consists of 90% phospholipids
(primarily phosphatidylcholine and phosphatidylglycerol) and 10% proteins (surfactant proteins [SP]-A,
SP-B, SP-C). Surfactant is packaged into lamellar bodies and is excreted into the alveolar space where it
unravels and forms a monolayer on alveolar surfaces. Lamellar bodies can also pass into the amniotic
cavity and, hence, are found in amniotic fluid. The surfactant functions to reduce the surface tension in the
alveoli, preventing atelectasis. When surfactant is deficient, the small alveoli collapse and the large alveoli
become overinflated and stiff, which has been associated with increased risk of developing respiratory
distress. The status of fetal lung maturity is reflected in the concentration of surfactant in the form of
phospholipids (see also FLP/8929 Fetal Lung Profile, Amniotic Fluid) and lamellar bodies present in
amniotic fluid. Lamellar bodies are similar in size to platelets and can be quantified on a hematology
analyzer utilizing the platelet channel and used to estimate fetal lung maturity. FLP/8929 Fetal Lung
Profile, Amniotic Fluid and LBC/60450 Lamellar Body Count, Amniotic Fluid are individually orderable.
A reflexive testing algorithm (LBCR/61179 Lamellar Body Count Reflex, Amniotic Fluid) is available to
reflex indeterminate lamellar body count results for FLP/8929 Fetal Lung Profile, Amniotic Fluid
(lecithin/sphingomyelin [L/S] ratio and phosphatidylglycerol [PG] testing).
Useful For: Predicting fetal lung maturity and assessing the risk of developing neonatal respiratory
distress syndrome, when performed during 32 to 39 weeks gestation
Interpretation: Amniotic fluid lamellar body count (LBC) >50,000/mcL is predictive of fetal lung
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1086